Trial Profile
Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2013
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary) ; Ganciclovir
- Indications Cytomegalic inclusion disorders
- Focus Therapeutic Use
- 22 Jul 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 18 Jan 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 22 Nov 2005 New trial record.